FindTrial
Sign In

Analysis of Prescription for correctness, cost effective ness, compliance and side effects and quality of Life in Type 2 Diabetes and Hypertension patients

A Comprehensive Prospective Analysis of Prescribing Indicators, Pharmacoeconomics, Therapeutic Adherence, Adverse Drug Reactions and Quality of Life Among Patients of Type 2 Diabetes Mellitus with Hypertension in A Tertiary Care Hospital - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/075904
Enrollment
385
Registered
2024-10-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E08-E13- Diabetes mellitus Health Condition 2: E00-E89- Endocrine, nutritional and metabolic diseases Health Condition 3: E11- Type 2 diabetes mellitus Health Condition 4: E118- Type 2 diabetes mellitus with unspecified complications

Interventions

Control Intervention1: NIL: Observational Study

Sponsors

Rama Medical College and Research Center Kanpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult patients aged 18 years and above. 2. Patients willing to provide informed consent for participation in the study. 3. Patients with HbA1c (6.5mmol/l - 9.4mmol/l) 4. Confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) and hypertension documented in medical records. 5. Patients receiving treatment for both T2DM and hypertension at the outpatient departments of the tertiary care hospital. 6. Patients with stage 1 and stage 2 hypertension

Exclusion criteria

Exclusion criteria: 1. Patients with Type 1 Diabetes Mellitus or secondary causes of hypertension. 2. Patients with Hypertensive emergency and urgency 3. Patients with HbA1c >9.4 mmol/l 4. Patients with severe cognitive impairment or communication barriers hindering participation in study assessments.

Design outcomes

Primary

MeasureTime frame
Pharmacoeconomic alaysis including cost effectiveness Therapeutic adherence Adverse drug reactions (ADRs)Timepoint: 4 weeks 12 Weeks 24 Weeks—

Secondary

MeasureTime frame
Pharmacoeconomic analysis and quality of life analysisTimepoint: At intervals of 3 months—

Countries

India

Contacts

Public ContactSeema Mishra

Rama Medical College Hospital and Research Centre, Mandhana, Kanpur

drnilamnigam@gmail.com9140190476

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026